NEW YORK–(BUSINESS WIRE)–David Benshoof Klein, founder and chief executive officer of Click Therapeutics, has been honored as a PharmaVoice 100 winner. The annual list recognizes the most inspiring people in the life sciences industry.
David is a healthcare innovator and entrepreneur with more than 20 years of experience in the life sciences industry. He is a staunch advocate for rigorous development and high-quality evidence standards for prescription digital therapeutics. His mission is to create safer and more efficacious treatments through the combination of software and drugs, and he believes collaborations between tech and pharma will revolutionize the standard of care and improve access to high-quality medical treatments globally.
“I am honored to be recognized by PharmaVoice, alongside other esteemed life science leaders,” shared Klein. “This recognition is a testament to the incredible team of innovators at Click Therapeutics, and it affirms the opportunity for digital therapeutics to bridge gaps in care and improve patient outcomes.”
PharmaVoice100 honorees are selected from a pool of nominations submitted by readers and colleagues, evaluated by the PharmaVoice team, then categorized into 10 distinct groups: Standout Leaders, Cancer Care Visionaries, Cardiometabolic All-Stars, Trailblazers, Biotech Pathfinders, Rare Disease Warriors, Tech and AI Wizards, Clinical Trial Pros, Patient Champions, and Cell and Gene Therapy Pioneers. Each winner represents the transformative impact of the pharmaceutical industry in their own unique way.
“These honorees are inspirations. Their teams look to them for guidance, their patients for support, and their organizations for direction. Each winner represents progress toward a healthier future for everyone that is bolstered by science and technological advancements. We are excited to recognize their contributions through this annual list,” said Meagan Parrish, lead editor of PharmaVoice.
From academia and nonprofits to Big Pharma, startups and tech companies, the PharmaVoice 100 list is the only awards program recognizing individuals from all sectors of life sciences. The highly anticipated list includes honorees from the clinic to the C-suite level who make meaningful contributions to their industry.
About Click Therapeutics
Click Therapeutics, Inc. develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, we deliver accessible, clinically validated, FDA-regulated prescription treatments to the smartphone in your hand. Our treatments are defined by our commitment to applying technical and scientific rigor and patient-centric design to the development process. This results in uniquely engaging experiences that achieve compelling clinical outcomes for patients seeking new treatment options. We are continuously expanding and refining our shared platform technologies with novel cognitive, behavioral and neuromodulatory mechanisms of action and advanced data-driven tools such as artificial intelligence and machine learning.
Click Therapeutics, in collaboration with Otsuka, developed the first prescription digital therapeutic authorized by the FDA for the adjunctive treatment of major depressive disorder symptoms, Rejoyn™. Digital therapeutics under development on Click’s platform address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases.
Consistently named the best place to work, we foster an inclusive, diverse workforce of innovators, clinicians, scientists, researchers, designers, technologists, engineers and more, united in our mission to provide patients everywhere access to safe and effective prescription digital therapeutics.
About PharmaVoice
PharmaVoice is a leading industry publication operated by Industry Dive. Our stories deliver the most important voices and ideas in the life sciences to industry leaders.
About Industry Dive
Industry Dive, an Informa business, is a leading business journalism company. Over 14 million decision-makers across 20+ competitive industries rely on our exclusive insight and analysis delivered through more than 30 publications.
